What is it about?
FC-99 (N1-[(4-methoxy)methyl],-4-methyl-1,2-benzenediamine) was a benzenediamine analog synthesized in our lab. In the previous studies, FC-99 displayed an anti-inflammatory effect and a therapeutic potential on experimental sepsis. It further inhibited the LPS-induced phosphorylation of NF-κB, which were associated with M1 macrophage polarization. However, whether FC-99 directly modulates the M1/M2 polarization and the underlying mechanism of action remains unknown. Herein, this paper suggests that FC-99 could modulate macrophage polarization and is a possible therapeutic candidate for acute sepsis-induced liver injury.
Featured Image
Photo by Christian Widell on Unsplash
Why is it important?
This study was designed to explore the effect of FC-99 on macrophage polarization in vitro and lipopolysaccharide- (LPS-) induced liver injury followed by the underlying mechanisms. For in vitro experiments, FC-99 inhibited M1-related macrophage factors and promoted M2-related markers induced by IL-4 in the mouse macrophage cell line. Moreover, FC-99-induced macrophages polarized to M2 phenotype which could be repressed by a PPAR-γ inhibitor but not STAT6 siRNA knockdown, indicating FC-99-induced M2 macrophage polarization through PPAR-γ rather than STAT6 signal. In LPS-induced septic mice, FC-99 pretreated mice displayed lower expression of M1 markers together with the increased M2 marker CD206 and improvement of liver injury.
Perspectives
Read the Original
This page is a summary of: A Benzenediamine Analog FC-99 Drives M2 Macrophage Polarization and Alleviates Lipopolysaccharide- (LPS-) Induced Liver Injury, Mediators of Inflammation, July 2019, Hindawi Publishing Corporation,
DOI: 10.1155/2019/7823069.
You can read the full text:
Contributors
The following have contributed to this page